ISSN:
1432-1041
Keywords:
ductus arteriosus
;
neonatal pulmonary circulation
;
prostaglandins
;
indomethacin
;
respiratory distress syndrome
;
congenital heart malformations
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Research in the past few years has established that prostaglandins, specifically prostaglandin (PG) E2, are responsible for keeping the ductus arteriosus patent in the fetus. Another prostaglandin, PGI2, is likely involved in the pulmonary vasodilation occurring at birth. This knowledge has afforded a new approach in the management of several pathological conditions of the newborn. PGE2 and structurally related PGE1 are currently used in newborns with congenital heart lesions requiring patency of the ductus to maintain the pulmonary or systemic circulation. Conversely, inhibitors of prostaglandin synthesis are used for closing a patent ductus in the premature infant. Preliminary experience indicates that PGI2 can be useful in the treatment of pulmonary hypertensive disorders of the neonate.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00561482
Permalink